文献速递类风湿关节炎

托珠单抗与依那西普治疗类风湿关节炎的心血管安全性随机对照试验

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2020-01-01

该随机开放标签平行组试验纳入3080例活动性血清阳性类风湿关节炎且至少有一项心血管危险因素、对传统合成改善病情抗风湿药应答不足的患者,1:1接受托珠单抗8 mg/kg/月或依那西普50 mg/周,平均随访3.2年。托珠单抗组主要不良心血管事件(MACE)风险比为1.05(95%CI 0.77-1.43),排除了MACE风险达1.43或以上的可能,但托珠单抗组严重感染和胃肠道穿孔等不良事件更常见。

要点

  • 托珠单抗相对依那西普的MACE风险比为1.05(95%CI 0.77-1.43)。
  • 该试验排除了托珠单抗MACE风险1.43或以上的可能。
  • 托珠单抗组严重感染和胃肠道穿孔等不良事件更常见。

核心结论

  • 托珠单抗相对依那西普未显示MACE风险升高,风险比为1.05(95%CI 0.77-1.43),排除了1.43或以上的风险。
  • 托珠单抗组不良事件更频繁,包括严重感染和胃肠道穿孔。

研究设计与样本

  • 随机、开放标签、平行组试验,纳入3080例活动性血清阳性RA且至少有一项心血管危险因素、对传统合成DMARDs应答不足的患者。
  • 患者1:1随机接受开放标签托珠单抗8 mg/kg/月或依那西普50 mg/周,平均随访3.2年。

主要发现

  • 治疗第4周,托珠单抗组相较依那西普组低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯水平中位数分别高11.1%、5.7%和13.6%(各P < 0.001)。
  • 随访期间托珠单抗组发生83例MACE,依那西普组发生78例MACE。
  • 托珠单抗相对依那西普的MACE风险比为1.05(95%CI 0.77-1.43),敏感性分析和在治疗人群分析结果相似。
  • 托珠单抗组不良事件更频繁,包括严重感染和胃肠道穿孔。

关键数值与推荐

  • 主要终点为首次MACE发生时间的比较,试验把握度设计为排除托珠单抗组相对依那西普组MACE风险比1.8或以上。
  • 托珠单抗组相对依那西普组MACE风险比为1.05(95%CI 0.77-1.43)。

临床怎么用

  • 对于有心血管危险因素的活动性血清阳性RA患者,托珠单抗的心血管安全性在MACE方面与依那西普相当,但需关注严重感染和胃肠道穿孔风险。
  • 临床决策应结合托珠单抗的疗效和非心血管安全性综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with tocilizumab compared to those treated with the tumor necrosis factor inhibitor etanercept. METHODS: This randomized, open-label, parallel-group trial enrolled patients with active seropositive RA (n = 3,080) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs and who had at least 1 cardiovascular (CV) risk factor. Patients were randomly assigned 1:1 to receive open-label tocilizumab at 8 mg/kg/month or etanercept at 50 mg/week. All patients were followed up for a mean of 3.2 years. The primary end point was comparison of time to first occurrence of MACE. The trial was powered to exclude a relative hazard ratio for MACE of 1.8 or higher in the tocilizumab group compared to the etanercept group. RESULTS: By week 4 of treatment, the serum low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were a median 11.1%, 5.7%, and 13.6% higher, respectively, in patients receiving tocilizumab compared to those receiving etanercept (each P < 0.001). During follow-up, 83 MACE occurred in the tocilizumab group compared to 78 MACE in the etanercept group. The estimated hazard ratio for occurrence of MACE in the tocilizumab group relative to the etanercept group was 1.05 (95% confidence interval 0.77-1.43). Results were similar in sensitivity analyses and in the on-treatment population analysis. Adverse events occurred more frequently in the tocilizumab group, including serious infection and gastrointestinal perforation. CONCLUSION: The results of this trial, which provide insights into the CV safety of tocilizumab as compared to etanercept, ruled out a risk for occurrence of MACE of 1.43 or higher in patients treated with tocilizumab. This result should be interpreted in the context of the clinical efficacy and non-CV safety of tocilizumab.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Giles JT, Sattar N, Gabriel S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020. PMID: 31469238. doi:10.1002/art.41095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。